See today's BioWorld Asia
To read the full story, subscribe or sign in.

Ideaya nabs Biocytogen’s bispecific ADC program for $406M

Aug. 6, 2024
By Marian (YoonJee) Chu
Ideaya Biosciences Inc. bought global rights to Biocytogen Pharmaceuticals Co. Ltd.’s cancer-targeting bispecific antibody-drug conjugate (bsADC) program in a deal reaching up to $406.5 million.
BioWorld Asia Deals and M&A Cancer Antibody-drug conjugate Asia-Pacific China U.S.